1221343-14-1

Basic information

• Product Name: 1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid
• Synonyms: 1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid;5-Carboxy-2-(hydroxymethyl)benzeneboronicaciddehydrate;1,3-Dihydro-1-hydroxy-2,1-benzoxaborole-6-carboxylic acid;1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxylic acid(WX191629)
• CAS NO: 1221343-14-1
• Molecular Formula: C₈H₇BO₄
• Molecular Weight: 177.94978
• Mol File: 1221343-14-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid(1221343-14-1)
• EPA Substance Registry System: 1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid(1221343-14-1)

Safety Data

• Hazardous Substances Data: 1221343-14-1(Hazardous Substances Data)

Usage

General Description

1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid is a chemical compound that belongs to the class of benzoxaboroles. It is a boron-containing compound with a hydroxyl group and carboxylic acid functionality. This chemical has shown potential as a pharmaceutical agent, with applications in the treatment of various diseases and conditions. It is of interest in medicinal chemistry due to its ability to form covalent bonds with biological molecules, making it a useful tool for drug discovery and development. Additionally, 1-Hydroxy-1,3-dihydro-2,1-benzoxaborole-6-carboxylic acid has demonstrated anti-inflammatory and antifungal properties, further diversifying its potential applications in the field of medicine.

Upstream product

• 1221343-13-0 methyl 3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-4-methylbenzoate 
• 882679-40-5 methyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1080573-21-2 4-acetoxymethyl-3-bromobenzoic acid methyl ester 
• 78946-25-5 3-bromo-4-(bromomethyl)benzoic acid methyl ester 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 13815-89-9 2-bromobenzene-1,4-dicarbonyl dichloride 
• 18643-86-2 dimethyl 2-bromoterephthalate 
• 553-94-6 4-bromo-m-xylene 
• 586-35-6 2-bromo-1,4-benzenedicarboxylic acid 
• 1186377-08-1 dimethyl 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene-1,4-dicarboxylate 
• 1268336-25-9 4-cyano-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 201342-56-5 (2-bromo-4-cyanophenyl)methyl acetate 
• 90110-98-8 3-bromo-4-(hydroxymethyl)benzonitrile 
• 89891-69-0 3-bromo-4-formyl benzonitrile 

Downstream Products

• 1221343-15-2 C₁₄H₁₂BNO₆S 
• 1222009-53-1 1-hydroxy-N-phenyl-1,3-dihydrobenzo[c][1,2]oxaborole-6-carboxamide 

Relevant articles and documents

A benzoboroxole-functionalized monolithic column for the selective enrichment and separation of cis-diol containing biomolecules

A benzoboroxole-functionalized monolithic column was synthesized, which exhibited the best specificity and affinity towards cis-diol containing biomolecules as compared with the boronate affinity monolithic columns reported as well as significant secondar

GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X-R2, and wherein "X" is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (lla) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1'-X'-R2', in which either the moeities R1' or R2' or X' carry a drug that is covalently attached to the diboron compound.

BORON-CONTAINING DIACYLHYDRAZINES

The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.